Meta-Analysis of Randomised Clinical Trials Comparing Idarubicin + Cytarabine with Daunorubicin + Cytarabine as the Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukaemia

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Wang, Jing ^a   Yang, Yong Gong ^a   Zhou, Min ^a   Xu, Jing Yan ^a   Zhang, Qi Guo ^a   Zhou, Rong Fu ^a   Chen, Bing ^a   Ouyang, Jian ^a  

^a THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SENSITIVITY; EVENT FREE SURVIVAL; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; META ANALYSIS; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DAUNORUBICIN; HUMANS; IDARUBICIN; INDUCTION CHEMOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84875964386     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060699     Document Type: Article

References (43)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics. CA Cancer J Clin 60: 277-300.
2. Holowiecki J, Grosicki S, Giebel S, Robak T, Kyrcz-Krzemien S, et al. (2012) Cladribine, But Not Fludarabine, Added to Daunorubicin and Cytarabine During Induction Prolongs Survival of Patients With Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Study. J Clin Oncol 30 (20) (): 2441-8.
3. Holowiecki J, Grosicki S, Robak T, Kyrcz-Krzemien S, Giebel S, et al. (2004) Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia 18 (5) (): 989-97.
4. Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, et al. (2011) Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 29 (4) (): 369-77.
5. Candoni A, Martinelli G, Toffoletti E, Chiarvesio A, Tiribelli M, et al. (2008) Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years. Leuk Res 32 (12) (): 1800-8.
6. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, et al. (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115 (3) (): 453-74.
7. Berman E, Heller G, Santorsa J, McKenzie S, Gee T, et al. (1991) Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 77 (8) (): 1666-74.
8. Wiernik PH, Banks PL, Case DC Jr, Arlin ZA, Periman PO, et al. (1992) Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 79 (2) (): 313-9.
9. AML Collaborative Group (1998) A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. Br J Haematol 103 (1) (): 100-109.
10. Rowe JM, Tallman MS, (1997) Intensifying induction therapy in acute myeloid leukemia: has a new standard of care emerged? Blood 90 (6) (): 2121-26.
11. Löwenberg B, Downing JR, Burnett A, (1999) Acute myeloid leukemia. N Engl J Med 341 (14) (): 1051-1062.
12. Pautas C, Merabet F, Thomas X, Raffoux E, Gardin C, et al. (2010) Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol 28 (5) (): 808-14.
13. Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, et al. (2011) Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood 117 (8) (): 2358-65.
14. Greenland S, (1994) Can meta-analysis be salvaged? Am J Epidemiol 140: 783-7.
15. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 151 (4) (): W65-94.
16. Liddle J, Williamson M, Irwig L, (1996) Method for evaluating research and guideline evidence. Sydney, NSW, NSW Department of Health.
17. Jüni P, Witschi A, Bloch R, Egger M, (1999) The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 282 (11) (): 1054-60.
18. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR, (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8: 16.
19. Parmar MK, Torri V, Stewart L, (1998) Extracting summary statistics to performmeta-analyses of the published literature for survival endpoints. Stat Med 17: 2815-34.
20. Cochran WG, (1954) The combination of estimates from different experiments. Biometrics 10: 101-29.
21. Berlin JA, Laird NM, Sacks HS, Chalmers TC, (1989) A comparison of statistical methods for combining event rates from clinical trials. Stat Med 8 (2) (): 141-51.
22. Poole C, Greenland S, (1999) Random-effects meta-analyses are not always conservative. Am J Epidemiol 150: 469-75.
23. Mantel N, Haenszel W, (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-48.
24. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7 (3) (): 177-88.
25. Begg CB, Mazumdar M, (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50 (4) (): 1088-101.
26. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (7109) (): 629-34.
27. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L, (2008) Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol 61: 991-6.
28. Altman DG, Bland JM, (2003) Interaction revisited: The difference between two estimates. BMJ 326: 219.
29. Mandelli F, Petti MC, Ardia A, Di Pietro N, Di Raimondo F, et al. (1991) A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA. Eur J Cance 27 (6) (): 750-5.
30. Vogler WR, Velez-Garcia E, Weiner RS, Flaum MA, Bartolucci AA, et al. (1992) A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol 10 (7) (): 1103-11.
31. Reiffers J, Huguet F, Stoppa AM, Molina L, Marit G, et al. (1996) A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75. Leukemia 10 (3) (): 389-95.
32. Rowe JM, Neuberg D, Friedenberg W, Bennett JM, Paietta E, et al. (2004) A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 103 (2) (): 479-85.
33. Gardin C, Turlure P, Fagot T, Thomas X, Terre C, et al. (2007) Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 109 (12) (): 5129-35.
34. Chevallier P, Fornecker L, Lioure B, Béné MC, Pigneux A, et al. (2010) Tandem versus single autologous peripheral blood stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: results of the multicenter prospective phase III GOELAMS LAM-2001 trial. Leukemia 24 (7) (): 1380-5.
35. Creutzig U, Ritter J, Zimmermann M, Hermann J, Gadner H, et al. (2001) Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group. Leukemia 15: 348-54.
36. Mandelli F, Vignetti M, Suciu S, Stasi R, Petti MC, et al. (2009) Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol 27: 5397-403.
37. Ferrara F, Palmieri S, Leoni F, (2008) Clinically useful prognostic factors in acute myeloid leukemia. Crit Rev Oncol Hematol 66 (3) (): 181-193.
38. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, et al. (2003) Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21 (24) (): 4642-9.
39. Roboz GJ, (2011) Novel approaches to the treatment of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2011: 43-50.
40. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, et al. (2009) Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 361 (13) (): 1249-59.
41. Lee JH, Joo YD, Kim H, Bae SH, Kim MK, et al. (2011) A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood 118 (14) (): 3832-41.
42. Löwenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, et al. (2009) High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 361 (13) (): 1235-48.
43. Begg CB, Berlin JA, (1988) Publication bias: a problem in interpreting medical data. J R Stat Soc Series A 151: 419-463.